CSL Ltd (CSLLY)
CSL Ltd, listed on OTC Markets as a depositary receipt representing common stock, is a global biopharmaceutical company headquartered in Melbourne, Australia. The business is active in research, development, manufacturing, marketing, and distribution of biopharmaceutical products and vaccines across Australia, the United States, Europe, and parts of Asia. Its operations are organized into three segments: CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring focuses on plasma-derived products, gene therapies, and recombinant medicines used in immunology, hematology, cardiovascular and metabolic disorders, respiratory conditions, and transplant care. CSL Seqirus develops and distributes influenza products and pandemic-related services for governments. CSL Vifor centers on treatments for iron deficiency and nephrology, and the company also licenses intellectual property. CSL Limited was founded in 1916.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CSLL.Y
|
$31.40
|
48.0% Upside
|
Undervalued
|
$24.10
|
13.6% Upside
|
Fair
|
Great
|
—
|
—
|
0.67
|
2.7%
|
August 18, 2026
|
29.5x
|
2.2x
|
2.7x
|
40.805 B
|
53.537 B
|
20.6%
|
99.9%
|
10.2
|
101.5%
|
218.5%
|
